Department of Transfusion Medicine & Cell Therapy, Kyoto University Hospital, 54 Kawahara-cho Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
Cancer Lett. 2010 Aug 28;294(2):245-53. doi: 10.1016/j.canlet.2010.02.008. Epub 2010 Mar 4.
Although novel agents effective against malignant mesothelioma (MM) have been developed, the prognosis of patients with MM is still poor. We generated a DNA-chimeric siRNA against polo-like kinase-1 (PLK-1), which was more stable in human serum than the non-chimeric siRNA. The chimeric PLK-1 siRNA inhibited MM cell proliferation through the induction of apoptosis. Next, we investigated the effects of zoledronic acid (ZOL) on MM cells, and found that ZOL also induced apoptosis in MM cells. Furthermore, ZOL augmented the inhibitory effects of the PLK-1 siRNA. In conclusion, combining a PLK-1 siRNA with ZOL treatment is an attractive strategy against MM.
虽然已经开发出了针对恶性间皮瘤 (MM) 的新型有效药物，但 MM 患者的预后仍然很差。我们生成了针对丝氨酸/苏氨酸激酶 polo-like kinase-1 (PLK-1) 的 DNA 嵌合 siRNA，与非嵌合 siRNA 相比，该嵌合 siRNA 在人血清中更稳定。嵌合 PLK-1 siRNA 通过诱导细胞凋亡抑制 MM 细胞增殖。接下来，我们研究了唑来膦酸 (ZOL) 对 MM 细胞的作用，发现 ZOL 也能诱导 MM 细胞凋亡。此外，ZOL 增强了 PLK-1 siRNA 的抑制作用。总之，将 PLK-1 siRNA 与 ZOL 联合治疗是一种有吸引力的 MM 治疗策略。
